Systemic sclerosis (SSc) is a multi-system autoimmune disorder characterized by widespread vascular lesions and fibrosis of the skin and internal organs^[@bibr1-2045894018816089]^ with a shortened survival rate mainly due to lung and heart disease related to heart failure. Heart involvement is reported in approximately 30% of SSc patients.^[@bibr2-2045894018816089]^ A large number of studies have investigated heart diseases in SSc patients using different non-invasive modalities, mainly echocardiography.^[@bibr3-2045894018816089][@bibr4-2045894018816089][@bibr5-2045894018816089][@bibr6-2045894018816089][@bibr7-2045894018816089]--[@bibr8-2045894018816089]^

Heart failure with preserved ejection fraction (HFpEF) due to diastolic dysfunction may be challenging to diagnose, even with invasive hemodynamic data.^[@bibr9-2045894018816089]^ For this reason, there is an increasing use of fluid challenge test (FCT) in the catheterization laboratory. In fact, acute volume loading increases left ventricular end-diastolic volume and filling pressures^[@bibr10-2045894018816089]^ and is useful for unmasking hidden post-capillary pulmonary hypertension (PH).^[@bibr11-2045894018816089]^

The aim of this study was to evaluate the hemodynamic changes of the pulmonary circulation after a FCT in SSc patients without PH.

Methods {#sec2-2045894018816089}
=======

This was a prospective, single-center study. All consecutive patients with SSc meeting the 2013 American College of Rheumatology/European League against Rheumatism classification criteria (12) referred to the Pulmonary Hypertension Unit of Monaldi Hospital, Naples (Italy), to undergo right heart catheterization (RHC) for suspicion of PH, between 1 January 2014 and 31 December 2015, were considered.

All patients were assessed using the European Scleroderma Trials and Research Group minimal essential dataset.^[@bibr13-2045894018816089]^ Patients were divided into two subsets (diffuse or limited cutaneous SSc) according to the classification of LeRoy et al.^[@bibr14-2045894018816089]^ Autoantibody profile and capillaroscopic abnormalities were investigated as previously described.^[@bibr15-2045894018816089]^ Disease duration was calculated from the onset of Raynaud's phenomenon. Disease activity was assessed with the European Scleroderma Study Group activity index,^[@bibr16-2045894018816089],[@bibr17-2045894018816089]^ and disease extent and severity were assessed with the revised Medsger scale;^[@bibr18-2045894018816089]^ a score ≥ 1 was considered indicative of each organ/system involvement (i.e. for cardiac disease, at least the presence of a conduction defect and/or a left ventricular ejection fraction \<50%; and for lung disease, at least the presence of a lung diffusion for carbon monoxide and/or a forced vital capacity \<80% of the respective predicted values, the presence of bibasilar crackles at lung auscultation, bibasilar fibrosis at standard chest X-ray).

The patients underwent a step-by-step diagnostic work-up according to current guidelines on PH,^[@bibr19-2045894018816089]^ thus including clinical evaluation, lung function tests, echocardiography, chest high-resolution computed tomography scan and ventilation/perfusion scan.

The non-invasive score, named H~2~FPEF,^[@bibr20-2045894018816089]^ has been used to better characterize the patients and estimate the probability of HFpEF.

An invasive evaluation was decided only if thought to be clinically relevant.

RHC without sedation was performed by two experienced cardiologists (MD and ER). Measurements of right atrial pressure (RAP), right ventricular (RV) pressure, systolic, mean and diastolic pulmonary pressures (sPAP, mPAP, and dPAP, respectively), and pulmonary artery wedge pressure (PAWP) were taken at end-expiration. Cardiac output (CO) was measured by thermodilution using an average of at least three measurements. Pulmonary vascular resistance (PVR) was calculated as mPAP minus PAWP (transpulmonary pressure gradient \[TPG\]) divided by CO. The diastolic pressure gradient (DPG) was calculated as dPAP minus PAWP.

FCT was performed as previously described^[@bibr11-2045894018816089]^ by intravenous administration of 7 mL/kg saline over 5--10 min during RHC. All hemodynamic measurements were repeated immediately after the end of the saline administration.

All SSc patients not satisfying the criteria for PH diagnosis (mPAP \< 25 mmHg) and age- and sex-matched controls were enrolled in this study. The presence of atrial fibrillation or flutter was considered exclusion criteria.

All patients gave written informed consent and the study was approved by the Institutional Review Board at Monaldi Hospital, Naples (Italy).

Results are reported as mean ± standard deviation unless otherwise noted. In between-group differences, continuous variables were compared by Kruskal--Wallis tests, whereas categorical variables were compared by Student--Newman--Keuls test.

Statistical analysis was performed using MedCalc, version 16.4.3 (MedCalc Software, Ostend, Belgium).

Results {#sec3-2045894018816089}
=======

SSc group {#sec4-2045894018816089}
---------

The SSc study group consisted of 25 patients (23 women; mean age = 66 ± 9 years; median disease duration = 14 years; range = 1--50 years).

Data on clinical, serological characteristics, organ involvement, and therapies are available for 21/25 patients and are listed in [Table 1](#table1-2045894018816089){ref-type="table"}. Table 1.Clinical, serological characteristics, organ involvement, and therapies at baseline of the 21/25 patients with systemic sclerosis.CharacteristicsDisease subtype and clinical manifestations lcSSc17/21 (81) dcSSc4/21 (19) Years from RP (median, range)14 (1--50) RP20/21 (95.2) Scleroderma1/21 (4.8) Median modified Rodnan skin score  (median, range)1.5 (0--10) Telangiectasia18/21 (85.7) History of and/or active DU and/or pitting scars13/21 (61.9) Sinovytis1/21 (4.8) Muscle weakness and/or CK elevation9/21 (42.8) Melanoderma1/21 (4.8) Gastrointestinal involvement17/21 (81) History of renal crisis0Autoantibodies ANA21/21 (100) ACA9/21 (42.9) ATA10/21 (47.6) RNA pol III0 PM-Scl0 Fibrillarin0 Negative SSc-marker autoantibodies0Features of lung involvement FVC \< 80% predicted7/21 (33.3) DLCO \< 80% predicted16/21 (76.2) ILD on HRCT of the lungs10/21 (47.6)EScSG-AI (median, range)1.75 (0--3)EScSG-AI ≥ 33/21 (14.3)Therapies Proton pump inhibitors21/21 (100) Low-dose aspirin21/21 (100) Calcium channel blockers21/21 (100) Glucocorticoids + vitamin D16/21 (76) Immunosuppressants11/21 (52) ACE-I/ARB12/21 (57) Prostanoids1/21 (5)[^1][^2]

All patients were treated with low-dose aspirin, nifedipine (20--60 mg), and proton pump inhibitors. In addition, 12/21 (57%) patients were also treated with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for systemic hypertension, 16/21 (76%) received low-dose corticosteroids (≤10 mg prednisone equivalent) and vitamin D supplementation, 11/21 (52%) received low-dose pulse cyclophosphamide (500 mg up to a cumulative dose of 10 g) administered for either active alveolitis or early diffuse disease and followed by either azathioprine or mycophenolate mofetil, and 1/21 (5%) received intercurrent iloprost infusion for ischemic ulcers developed despite treatment with calcium channel blockers. No patient was under diuretic treatment.

Of 21 SSc patients, two (10%) had diabetes, three (14%) had coronary artery disease, four (19%) had hyperlipidemia, and one (5%) had severe obesity (body mass index \[BMI\] \> 30 kg/m^2^). The mean H~2~FPEF score was 1.3 ± 0.8.

Controls {#sec5-2045894018816089}
--------

A total of 25 sex-, age-, weight-, and body surface area-matched controls (23 women; mean age = 65 ± 9 years) admitted to the Cardiology Unit of Monaldi Hospital, Naples (Italy), to undergo clinically indicated RHC and that showed normal pulmonary pressure (mPAP \<25 mmHg) were selected for comparison.

Of 25 controls, 13 (52%) had hypertension and were on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, three (12%) had diabetes, (16%) four had coronary artery disease, four (16%) had hyperlipidemia, and one (4%) had severe obesity (BMI \> 30 kg/m^2^). The mean H~2~FPEF score was 1.2 ± 0.8.

No patient was under diuretic treatment.

Hemodynamics {#sec6-2045894018816089}
------------

Demographics, clinical, and echocardiographic features of SSc patients and controls are shown in [Table 2](#table2-2045894018816089){ref-type="table"}. Baseline hemodynamics are shown in [Table 3](#table3-2045894018816089){ref-type="table"}. Table 2.Demographic, clinical, and echocardiographic features.Control (n = 25)SSc (n = 25)*P* valueFemale sex (%)23 (92%)23 (92%)1.0BSA (m^2^)1.7 ± 0.21.6 ± 0.10.67Age (years)65 ± 966 ± 90.60WHO FC I20 (80%)17 (68%) II5 (20%)8 (32%) III0 (0%)0 (0%) IV0 (0%)0 (0%)Systolic BP (mmHg)126 ± 14130 ± 150.39Diastolic BP (mmHg)69 ± 669 ± 70.92Heart rate (bpm)77 ± 979 ± 100.42H~2~FPEF score1.3 ± 0.81.2 ± 0.80.48Echocardiography LAVI (mL/m^2^)23 ± 725 ± 60.11 LVEDd (mm)45 ± 547 ± 60.28 LVESd (mm)28 ± 529 ± 40.15 IVS (mm)10 ± 310 ± 40.79 PW (mm)9 ± 48 ± 40.26 LVEF (%)60 ± 562 ± 40.18 TAPSE (mm)24 ± 522 ± 40.29 IVC (mm)14 ± 613 ± 80.32 E/A1.4 ± 0.51.2 ± 0.40.15 E/e′5.8 ± 2.07.2 ± 2.70.02[^3][^4] Table 3.Baseline hemodynamics.Control (n = 25)SSc (n = 25)*P* valueRAP (mmHg)4 ± 14 ± 20.49RV systolic pressure (mmHg)28 ± 630 ± 60.27Systolic PAP (mmHg)27 ± 629 ± 60.15Mean PAP (mmHg)18 ± 319 ± 30.10Diastolic PAP (mmHg)11 ± 212 ± 30.6PAWP (mmHg)8 ± 29 ± 30.58PAWP--RAP (mmHg)4 ± 24 ± 20.90Cardiac index (L/min·m^2^)3.3 ± 0.53.3 ± 0.50.83PVR (Wood Units)1.8 ± 0.72.0 ± 0.90.23TPG (mmHg)9 ± 311 ± 30.21DPG (mmHg)3 ± 23 ± 30.21[^5][^6][^7]

A higher E/e′ in SSc than in controls (7.2 ± 2.7 vs. 5.8 ± 2.0; *P* = 0.02) was the only difference between the two groups at echocardiographic evaluation.

Blood pressure, heart rate, and all hemodynamics did not differ between groups.

Notably, 9/25 SSc patients (36%) and 6/25 controls (24%) showed mPAP in the range of 21--24 mmHg and 4/25 SSc patients (16%) and 2/25 controls (8%) showed PAWP in the range of 12--15 mmHg.

FCT was well tolerated and no patient in both groups developed significant side effects.

Hemodynamics after fluid challenge are shown in [Table 4](#table3-2045894018816089){ref-type="table"}, with changes in [Table 5](#table4-2045894018816089){ref-type="table"}. CO, RAP, RV pressure, sPAP, mPAP, dPAP, and PAWP increased in both groups. The increase in pressure values was proportionally larger and the increase in CO lower in SSc patients compared to controls. PVR, TPG, and DPG did not significantly change after FCT in both groups. Table 4.Hemodynamics after fluid challenge.Control (n = 25)SSc (n = 25)*P* valueRAP (mmHg)6 ± 17 ± 20.03RV systolic pressure (mmHg)31 ± 635 ± 60.04Systolic PAP (mmHg)30 ± 634 ± 60.04Mean PAP (mmHg)21 ± 324 ± 30.0002Diastolic PAP (mmHg)14 ± 217 ± 30.0001PAWP (mmHg)12 ± 314 ± 30.005PAWP--RAP (mmHg)5 ± 27 ± 30.077Cardiac index (L/min·m^2^)4.0 ± 0.53.7 ± 0.60.13PVR (Wood Units)1.4 ± 0.61.7 ± 0.70.10TPG (mmHg)9 ± 310 ± 30.25DPG (mmHg)2 ± 13 ± 30.41[^8][^9][^10] Table 5.Fluid challenge-induced changes in hemodynamics.Control (n = 25)SSc (n = 25)*P* valueΔ RA systolic pressure (mmHg)2 ± 13 ± 10.03Δ RV systolic pressure (mmHg)3 ± 14 ± 20.001Δ Systolic PAP (mmHg)3 ± 14 ± 20.026Δ Mean PAP (mmHg)3 ± 15 ± 1 \<0.001Δ Diastolic PAP (mmHg)3 ± 15 ± 1\<0.001Δ PAWP (mmHg)3 ± 15 ± 2\<0.001Δ PAWP-RAP (mmHg)1 ± 22 ± 20.02Δ Cardiac index (L/min·m^2^)0.6 ± 0.30.4 ± 0.20.004Δ PVR (Wood Units)−0.4 ± 0.4−0.3 ± 0.50.87Δ TPG (mmHg)0 ± 1−1 ± 20.87Δ DPG (mmHg)0 ± 1−1 ± 20.44[^11][^12][^13][^14]

Four out of 25 SSc patients (16%) and 1/25 controls (4%) showed a PAWP ≥ 18 mmHg after fluid challenge. During a three-year follow-up, two patients developed HFpEF, both with SSc and a PAWP ≥ 18 mmHg after fluid challenge.

Discussion {#sec7-2045894018816089}
==========

The main finding of the present study is that fluid challenge with a rapid infusion of 7 mL/kg saline over 5--10 min at RHC induces a larger increase of pulmonary pressures and a smaller increase of flow in SSc patients without PH compared to controls.

Recently, a scoring system based on clinical and echocardiographic findings aimed to discriminate HFpEF from non-cardiac causes of dyspnea has been developed by Reddy et al.^[@bibr20-2045894018816089]^ and then validated in a separate test cohort. This score, named H~2~FPEF, is based on the presence of six features: obesity; hypertension; atrial fibrillation; pulmonary hypertension; age \> 60 years; and E/e′ \> 9. The author found that the H~2~FPEF score might be used to rule out the HFpEF among patients with low scores (e.g. 0 or 1) and to establish the diagnosis of HFpEF with reasonably high confidence at higher scores (e.g. 6--9). They suggest using additional tests for patients with intermediate scores (e.g. 2--5).

Among the four individuals showing a PAWP ≥ 18 mmHg after fluid challenge, three (two SSc patients and one control) had a H~2~FPEF score of 2 and one (SSc patients) had a H~2~FPEF score of 3.

HFpEF due to diastolic dysfunction may be challenging to diagnose, even with invasive hemodynamic data. These data underscore a different response to the fluid loading in SSc patients compared to controls and allows a more comprehensive decision-making process in patients with intermediate probability of HFpEF.

The diagnosis of post-capillary PH is based on a mPAP ≥ 25 mmHg and a PAWP \> 15 mmHg.^[@bibr19-2045894018816089]^ Moreover, current guidelines on PH^19^ recommend interpreting invasive hemodynamics in the context of the clinical picture and imaging. In fact, PAWP in PH due to left heart diseases may be found below the threshold of 15 mmHg in the resting state in patients with optimal therapy and volume depletion on diuretic intake. Based on this pathophysiological observation, an acute fluid loading has been increasingly used in daily practice as an adjunctive tool to discriminate between pre- and post-capillary PH.

Previous studies^[@bibr21-2045894018816089],[@bibr22-2045894018816089]^ showed that the upper limit of normal for PAWP after rapid infusion of 500 mL saline would be 18 mmHg. Recently, our group^11^ investigated the clinical relevance of a FCT systematically added to standard RHC in patients referred for suspicion or evaluation of PH. Prediction bands calculated from quadratic fits of the PAWP changes in pooled controls confirmed 18 mmHg as a valid cut-off value for diagnosing post-capillary PH. This cut-off value, together with other clinical and non-invasive tools such as echocardiography, allows reclassification of 6--8% of patients with pre-capillary PH or normal hemodynamics at baseline.

Lack of data exists so far for SSc patients. Fox et al.^[@bibr23-2045894018816089]^ reported on left- and right-sided heart catheterization in 107 patients with SSc. Based on mPAP and PAWP, 29 out of 107 patients received a diagnosis of pulmonary arterial hypertension (PAH) and 24 a diagnosis of post-capillary PH after baseline RHC. Eleven out of 29 patients with PAH (58%) were reclassified as post-capillary PH on the basis of a left ventricular end-diastolic pressure \>15 mmHg at baseline (n = 5) or after fluid challenge with 500 mL of saline over 5--10 min (n = 6). Thus, fluid challenge helped reclassify 22% of the patients otherwise thought to have PAH. Nevertheless, based on previous studies,^[@bibr11-2045894018816089],[@bibr21-2045894018816089],[@bibr22-2045894018816089]^ the threshold of 15 mmHg after fluid loading seems too low for identifying patients with post-capillary PH.

This was at the time the first study evaluating the hemodynamic changes after acute fluid loading in patients with SSc without PH. The data of the present study show that patients with SSc have a larger increase of PAWP probably due to their well-known left ventricular diastolic dysfunction. The increase in left ventricular filling pressure is backward transmitted and provokes a similar larger increase in pulmonary pressures compared to controls. These data may be particularly relevant because fluid loading is going to be standardized for the differential diagnosis between pre- and post-capillary PH, which remains challenging in older, overweight patients and individuals with cardiovascular risk factors showing ambiguous PAWP at baseline RHC. In addition, a larger increase of PAWP may also be considered a possible cause of otherwise unexplained effort dyspnea.

Our study also points out a larger increase of pulmonary vascular pressures after FCT in SSc patients than in controls. This finding is likely related to the "fixed" vascular system that is characteristic of SSc vasculature.^[@bibr24-2045894018816089]^ In fact, pulmonary vessels as well as vessels from other body districts are unable to undergo a vasodilatation similar to that occurring in normal controls.^[@bibr25-2045894018816089]^ This hypothesis appears to be supported by the concomitant smaller cardiac index increase after FCT compared to controls, which might reflect a reduced "preload reserve" of the ventricles. Moreover, because fluid challenge transiently increases systemic venous return, it may test the capacity of the right ventricle to adapt to a sudden increase in preload. Analogously, a reduced "contractile reserve" has been previously detected in SSc patients without PH by non-invasive study^[@bibr26-2045894018816089]^ using physical effort. Taken together, these data reflect an impaired capability of the right ventricle to cope with an increased volume or pressure in SSc patients.

Finally, it has recently been demonstrated that a cardiac index \<2.8 L/min/m^2^ after a fluid challenge is an independent predictor of clinical worsening in idiopathic PAH.^[@bibr27-2045894018816089]^ Therefore, we may speculate that an intrinsic reduction of the preload reserve in patients with SSc can play a role in the poorer prognosis of SSc patients when developing PAH.

Limitations {#sec8-2045894018816089}
-----------

This study has some limitations.

The main limitation is the small sample size, which not allows sub-group comparisons.

Both groups, SSc patients and controls, required an invasive evaluation for suspicion of PH; for this reason, at baseline 36% of SSc patients and 24% of controls showed a mPAP of 21--24 mmHg and 16% of SSc patients and 8% of controls showed a PAWP in the range of 12--15 mmHg. Therefore, it could be that SSc patients with no clinical indication to RHC and perfectly healthy controls would have a lower PAWP after a 7 mL/kg fluid challenge. Moreover, as we mainly looked for PAH, it is not known the response to FCT in patients with severe chronic lung diseases or hypoxia with and without SSc that did not undergo RHC because not clinically indicated.

Conclusions {#sec9-2045894018816089}
===========

In summary, SSc patients without PH have a larger increase of pulmonary pressures and a lower increase of flow compared to controls after an acute volume loading. This is probably due to subclinical left ventricular diastolic dysfunction and suggests a reduced preload reserve. This may have clinical relevance in identifying the limits of normal of hemodynamics in SSc patients undergoing FCT. Further larger studies are needed to confirm these findings.
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[^1]: Values are expressed as n (%), except where otherwise indicated.

[^2]: ACA, anticentromere antibodies; ACE-I, angiotensin-converting enzyme inhibitors; ANA, antinuclear antibodies; ARB, angiotensin receptor blockers; ATA, anti-topoisomerase I antibodies; dcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing lung capacity for carbon monoxide expressed as a percentage of the predicted value; DU, digital ulcers; EScSG-AI, European Scleroderma Study Group-Activity Index; FVC, forced vital capacity expressed as a percentage of the predicted value; HRCT, high resolution computed tomography; ILD, interstitial lung disease; lcSSc, limited cutaneous systemic sclerosis; RNA pol III, anti-RNA polymerase III; RP, Raynaud's phenomenon; SD, standard deviation; SSc, systemic sclerosis.

[^3]: Continuous variables are expressed as mean ± standard deviation.

[^4]: A, A wave; BP, blood pressure; bpm: beats per minute; BSA, body surface area; E, E wave; e', E wave at mitral annulus; H~2~FPEF, clinical and echocardiographic score for calculating the probability of heart failure with preserved ejection fraction; ICV, inferior cava vein; LAVI, left atrium volume index; IVS, interventricular septum; LVEDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESd, left ventricular end-systolic diameter; PW, posterior wall; TAPSE, tricuspid annulus plane systolic excursion; WHO FC, World Health Organization functional class.

[^5]: Continuous variables are expressed as mean ± standard deviation.

[^6]: *P* \< 0.05 vs. Control.

[^7]: DPG, diastolic pressure gradient; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricular; SSc, systemic sclerosis; TPG, transpulmonary pressure gradient.

[^8]: Values are expressed as mean ± standard deviation.

[^9]: *P* \< 0.05 vs. Control.

[^10]: DPG, diastolic pressure gradient; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricular; SSc, systemic sclerosis; TPG, transpulmonary pressure gradient.

[^11]: Values are expressed as mean ± standard deviation.

[^12]: *P* \< 0.05 vs. Control.

[^13]: : difference between before and after fluid challenge.

[^14]: DPG, diastolic pressure gradient; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right ventricular; SSc, systemic sclerosis; TPG, transpulmonary pressure gradient.
